Lumos Pharma Announces Departure of Chief Medical Officer
29 June 2023 - 6:01AM
Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company
advancing an oral therapeutic candidate for idiopathic Pediatric
Growth Hormone Deficiency (iPGHD) through Phase 2 clinical trials,
announced today that Chief Medical Officer (CMO) Dr. David B. Karpf
is departing the company to pursue other opportunities, effective
June 29th. Dr. Pisit “Duke” Pitukcheewanont, Lumos Pharma’s Senior
Vice President, Global Clinical Development and Medical Affairs,
along with other members of our clinical team, will oversee all
clinical activities and related functions until a CMO search is
complete.
“We thank David for his many contributions to
Lumos Pharma and know he will continue to advance the field of
endocrinology in his work with Stanford University,” said Rick
Hawkins, Chairman and Chief Executive Officer of Lumos Pharma. “Dr.
Duke Pitukcheewanont, a pediatric endocrinologist with over 25
years’ experience and President of the Human Growth Foundation for
12 years, has been instrumental in the recruitment and conduct of
our ongoing clinical trials. We are confident that Dr.
Pitukcheewanont, along with our experienced clinical team, will
continue to advance our programs effectively while we conduct a
search for a permanent CMO replacement to execute the rollout of
our planned Phase 3 development program.”
About Pediatric Growth Hormone Deficiency and
LUM-201
Pediatric Growth Hormone (GH) Deficiency is the
consequence of inadequate secretion of growth hormone from the
pituitary gland in children resulting in low GH in the body,
insufficient production of downstream signaling molecules required
for growth, and the subsequent lack of growth. LUM-201, also known
as ibutamoren, is an orally administered investigational small
molecule that promotes the secretion of GH from the pituitary gland
and represents an opportunity for appropriately selected patients
to avoid the daily or weekly injections involved with current or
forthcoming therapies. LUM-201 has been observed to increase the
amplitude of endogenous pulsatile GH secretion, which mimics the
natural pattern of GH secretion.
About Lumos Pharma
Lumos Pharma, Inc. is a clinical stage
biopharmaceutical company focused on the development and
commercialization of therapeutics for rare diseases. Lumos Pharma
was founded and is led by a management team with longstanding
experience in rare disease drug development. Lumos Pharma’s lead
therapeutic candidate is LUM-201, an oral growth hormone
stimulating small molecule, currently being evaluated in several
Phase 2 clinical trials for the treatment of idiopathic Pediatric
Growth Hormone Deficiency (iPGHD): the dose-finding OraGrowtH210
Trial; the PK/PD mechanistic OraGrowtH212 Trial; and a switch
trial, the OraGrowtH213 Trial. If approved by the FDA, LUM-201
would provide an orally administered alternative to recombinant
growth hormone injections that PGHD subjects otherwise endure for
many years of treatment. LUM-201 has received Orphan Drug
Designation in both the US and EU. For more information, please
visit https://lumos-pharma.com/.
Investor & Media Contact:
Lisa MillerLumos Pharma Investor
Relations512-792-5454ir@lumos-pharma.com
Lumos Pharma (NASDAQ:LUMO)
Historical Stock Chart
From Apr 2024 to May 2024
Lumos Pharma (NASDAQ:LUMO)
Historical Stock Chart
From May 2023 to May 2024